Corner Therapeutics

Executive Summary

Corner Therapeutics is a preclinical-stage biotechnology company based in Cambridge, MA, focused on developing innovative immunotherapies and targeted therapies for cancer and autoimmune diseases. Founded in 2020, the company has raised $54 million to advance its platform that aims to precisely modulate the immune system—either to attack tumors or restore immune tolerance. Its pipeline includes both biologic and small molecule candidates, though specific programs have not been publicly disclosed. Given the substantial funding and early-stage focus, Corner Therapeutics is positioned to address significant unmet needs in oncology and immunology. The company's success will depend on advancing its lead candidates into clinical development and demonstrating proof-of-concept in relevant models. As a private entity, its progress is closely watched by investors seeking exposure to novel immune-modulating approaches.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing40% success
• Q2 2027Series B Financing or Strategic Partnership60% success
• Q3 2026Preclinical Data Release for Autoimmune Indication70% success